OncoAlert

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025.

Discussing:

1. Association between risk-reducing surgeries and survival in young BRCA carriers with #BreastCancer 
2. DESTINY-Breast11 Update from Industry
3. PALMIRA in Breast #Cancer (Palbo rechallenge)
4. PEACE V STORM in #Prostate Cancer
5. MAGNITUDE :Niraparib and Abiraterone Acetate plus Prednisone in Met CR Prostate Cancer
6. OS EGFR-mutant AdvancedNon-Small Cell #LungCancer Treated with 1L Osimertinib 
7. Cemiplimab monotherapy as 1L treatment of patients with brain metastases from advanced #NSCLC with  PDL1 ≥50%
8. Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine 

and more

This international retrospective cohort study evaluated the safety of assisted reproductive technology (ART) in BRCA1/2 carriers who conceived after a breast cancer diagnosis at age 40 or younger. Among 543 women, 107 conceived using ART and 436 conceived spontaneously. ART methods included oocyte/embryo cryopreservation, in vitro fertilization, ovulation induction, and oocyte donation. Patients who used ART were generally older, had more hormone receptor-positive tumors, and a longer interval from diagnosis to conception. After a median follow-up of 5.2 years post-conception, ART use was not associated with an increased risk of disease-free survival events, suggesting that ART is a safe option for pregnancy after breast cancer in this population.

Join Dr. Jemal & Dr Morgan as they discuss this report, a collaboration among major U.S. cancer surveillance organizations, presents the latest national data on cancer incidence and mortality. Using data from cancer registries and national vital statistics, the analysis shows that while overall cancer death rates have steadily declined over the past 20 years — including during the COVID-19 pandemic — the annual rate of decline has recently slowed. Cancer incidence rates remained stable among males and rose slightly among females over time, with a temporary dip across all groups in 2020 likely due to pandemic-related disruptions in healthcare access. However, incidence rates rebounded to prepandemic levels by 2021, suggesting a limited long-term impact of COVID-19 on cancer detection trends.

https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833

Cohort study evaluated the use of ablative radiation therapy (A-RT) as a noninvasive alternative to surgery in 25 patients with technically resectable pancreatic ductal adenocarcinoma (PDAC) who were ineligible for surgery due to comorbidities. Conducted at Memorial Sloan Kettering Cancer Center between 2016 and 2022, the study found that A-RT, delivered with high precision and dose intensity, provided promising local control and overall survival, with a 2-year OS rate of 43.7% and manageable toxicity. Despite advanced age, poor performance status, and limited chemotherapy use in the cohort, outcomes suggest A-RT may be a viable local therapy for select patients with resectable PDAC, warranting further prospective investigation.

Link to Arcticle
https://jamanetwork.com/journals/jamaoncology/article-abstract/2832566

The OncoAlertWeekly Round Up   
Covering the TOP of the week April 18-24, 2025 

REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration   

Discussing:
UPDATE on DESTINY-Breast09
https://astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.html

UPDATE on ASCENT 04
https://gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-trip

Annual Report to the Nationon the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833

Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer
https://lungcancerjournal.info/article/S0169-5002(25)00443-X/fulltext

Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution
https://link.springer.com/article/10.1007/s11912-025-01655-5

Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djaf048/8101485?login=false

European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’
https://esmogastro.org/article/S2949-8198(25)00037-8/fulltext

Korea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different?
https://link.springer.com/article/10.1007/s10120-025-01613-x

Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring
https://ascopubs.org/doi/10.1200/OP-25-00062

Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancies
https://ascopubs.org/doi/10.1200/PO-24-00896?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Study compared the prognostic impact of differing high-risk inclusion criteria used in the monarchE and NATALEE trials among patients with hormone receptor-positive/HER2-negative early #BreastCancer , using data from the MIG1, GIM2, and GIM3 trials. Patients were stratified into high- and low-risk cohorts per each trial’s criteria, and further grouped into concordant low-risk, discordant risk, and concordant high-risk categories.

Link to Article
https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette

Oncology here & now

In this interview Dr. Biagio Ricciuti of Dana Farber Cancer Institute (USA) talks to Dr. Marcelo Corassa of beneficência Portuguesa de São Paulo (Brazil) as they discuss Treatments in EGFR mutant Non Small Cell Lung Cancer. The discussion centers around the results of FLAURA, MARIPOSA and FLAURA2, future directions and much more.

Join Us

Dear Colleagues,

Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:

Prognostic implications of risk definitions from the monarchE and NATALEE trial

https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djaf031/8002826?login=false#google_vignette

Evaluating the impact of histological vs. nuclear grading on CPS + EG Score for HR + /HER2-early breast cancer

https://link.springer.com/article/10.1007/s10549-025-07685-8?utm_content=buffer1d9c4&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-ipilimumab-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer

Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial

https://www.nature.com/articles/s41591-025-03579-w

Assessment of a Polygenic Risk Score in Screening for Prostate Cancer (BARCODE1) 

https://nejm.org/doi/full/10.1056/NEJMoa2407934

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer

https://www.nature.com/articles/s41467-025-58435-9

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

https://www.annalsofoncology.org/article/S0923-7534(25)00130-9/abstract

Dr. van der Wilk dives into the results of the SANO Trial in Oesophageal Cancer and recently published on the Lancet Oncology. 

The phase 3 trial investigated whether active surveillance could be a non-inferior alternative to standard surgery in individuals with oesophageal cancer who achieved a clinical complete response after neoadjuvant chemoradiotherapy. Conducted in 12 Dutch hospitals, the study randomized 309 participants to either active surveillance or standard oesophagectomy. After a median follow-up of 38 months, the 2-year overall survival for active surveillance (74%) was non-inferior to that of standard surgery (71%), with no significant differences in postoperative complications or mortality between groups. These results suggest active surveillance could be a viable option for patient counseling and shared decision-making, although extended follow-up is needed to assess long-term efficacy.